

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 2152
TO BE ANSWERED ON THE 10TH DECEMBER, 2021**

NASAL VACCINE FOR CHILDREN

2152. SHRIMATI JASKAUR MEENA:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Government proposes to introduce nasal vaccine for children across the country;
- (b) if so, the details thereof;
- (c) the details of the tests conducted so far along with the outcome thereof;
- (d) the time by which the nasal vaccine is likely to be launched; and
- (e) the other steps taken by the Government to protect the children from the third wave of COVID-19?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY
WELFARE
(DR. BHARATI PRAVIN PAWAR)**

(a) to (d) No Nasal vaccine trial for children is ongoing across the country. However, As of now,ZyCoV-D vaccine manufactured by M/s Cadila Healthcare has received the approval for Restricted Use in Emergency Setting by the National Regulator i.e. Drug Controller General of India (DCGI) for the age group of 12 years and above based on the interim clinical data of Phase III clinical trial conducted in the country.

Following COVID-19 vaccines are under clinical trials in the country for age-group of less than 18 years:

- i. M/s Bharat Biotech is conducting Phase II/III clinical trial of COVAXIN on Healthy Volunteers aged 2 to 18 years & firm has submitted interim safety & immunogenicity data to the National Regulator.
- ii. M/s Serum institute of India is conducting Phase II/III clinical trial of Nanoparticle Vaccine (Liquid) (COVOVAX) in 920 subjects of >2 to 17 years age group.
- iii. M/s Biological E Ltd., is conducting Phase II/III clinical trial of RBD of SARS-CoV-2 gene in 624 subjects of ≥ 5 to <18years age group.

- iv. M/s Johnson & Johnson Pvt. Ltd., is conducting Phase II/III clinical trial of Ad.26COV.2S vaccine in age group of 12-17 years (Global Clinical trial wherein India is one of the clinical trial site).

The approval of aforementioned COVID-19 vaccines depends on the successful completion of clinical trials and submission of requisite data as per the requirements of New Drugs and Clinical Trials Rules, 2019 under Drugs and Cosmetics Act, 1940.

(e)The guiding principle to minimize and avert the risk of future resurgence of Covid-19 cases is the 5-fold strategy of Test-Track-Treat-Vaccinate and COVID Appropriate Behaviour. Besides this States are also being provided requisite technical and financial support by the Government of India to prepare for and respond to any exigencies arising out of surge in Covid-19.

A new scheme 'India COVID-19 Emergency Response & Health System Preparedness Package: (ERCP-II)' amounting to Rs 23,123 crore has been approved for Financial year 2021-22 that aims to prevent, detect and respond to the continuing threat posed by COVID-19 and strengthen national health systems for preparedness in India for all.
